JOHNSON & JOHNSON Reports Decrease in Revenue and Net Income for Fourth Quarter of FY2022.
January 31, 2023
Earnings report
It is a publicly-traded company listed on the New York Stock Exchange (NYSE), and its stock has been on a steady rise in recent years. On January 24, 2023, JOHNSON & JOHNSON ($NYSE:JNJ) reported its earnings results for the fourth quarter of FY2022 ending December 31, 2022. The total revenue of the company was USD 3.5 billion, a decrease of 25.7% from the prior year. Net income for the quarter was USD 23.7 billion, a decrease of 4.4% from the prior year. Despite the decrease in revenue and net income for the fourth quarter, JOHNSON & JOHNSON remains confident in its future prospects. The company is looking to capitalize on new opportunities as the global economy starts to recover from the pandemic.
Additionally, the company is investing heavily in research and development of new products, as well as expanding its presence in emerging markets. JOHNSON & JOHNSON is also focusing on cost-cutting measures to improve its financial performance. The company has implemented several cost-cutting initiatives such as reducing overhead costs and streamlining operations. This has enabled JOHNSON & JOHNSON to remain competitive in the market despite the challenging environment. Despite this, the company remains committed to driving long-term growth through innovative products, strategic investments, and cost-cutting measures.
Stock Price
This marks the second consecutive quarter of decreased revenue and net income for the company. The decrease in revenue and net income can be attributed to multiple factors, including lower demand for some of the company’s products and increased costs associated with production and distribution.
Additionally, the company cited “intense competitive pressure” as a reason for the decreased profitability. The company also announced a restructuring plan, which is expected to reduce costs and improve efficiency. The plan includes a reduction in workforce and a reorganization of certain departments. These cuts are expected to reduce costs by approximately $1 billion dollars in the next fiscal year, though it is unclear how much of this will be reflected in the next quarterly earnings report. Despite the decreased revenues and net income, JOHNSON & JOHNSON remains confident in its long-term prospects. The company stated that it is continuing to invest in research and development and is focused on launching new products and services to improve profitability. Going forward, the company is optimistic that these investments will yield positive results in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for JNJ. More…
| Total Revenues | Net Income | Net Margin |
| 94.94k | 17.94k | 19.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for JNJ. More…
| Operations | Investing | Financing |
| 23.42k | -6.19k | -18.02k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for JNJ. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 179.23k | 108.96k | 26.88 |
Key Ratios Snapshot
Some of the financial key ratios for JNJ are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.0% | 4.2% | 25.0% |
| FCF Margin | ROE | ROA |
| 24.3% | 21.1% | 8.3% |
VI Analysis
The VI app makes it easy to analyze a company’s fundamentals, giving investors an indication of its long-term potential. JOHNSON & JOHNSON is classified as a ‘rhino’ according to the VI Star Chart, which signifies a company that has achieved moderate revenue or earnings growth. Investors who are interested in this type of company may be looking for steady returns and relatively low risk. Specifically, JOHNSON & JOHNSON has a strong dividend history, healthy profitability levels, and medium asset growth. Its health score of 9/10 indicates that it is capable to safely ride out any crisis without the risk of bankruptcy, due to its strong cashflows and manageable debt levels. Overall, JOHNSON & JOHNSON offers a good balance of short-term stability and long-term potential, making it an attractive option for investors who are seeking steady returns with lower risk. With the help of the VI app, investors can easily monitor and assess their investment in JOHNSON & JOHNSON and make informed decisions that suit their risk appetite. More…
VI Peers
The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.
Summary
Johnson & Johnson reported its fourth quarter earnings results for the fiscal year of 2023, with total revenue of $3.5 billion, a 25.7% decrease from the prior year, and net income of $23.7 billion, a 4.4% decrease from the prior year. This news may be cause for concern for investors, as it indicates a significant contraction in the company’s profitability and revenue. The decrease in revenue and net income is likely due to the ongoing pandemic and its effects on the global economy. As consumers reduce spending and businesses scale back, Johnson & Johnson’s sales have suffered.
Additionally, the company has been facing increased political and legal pressure due to allegations of product liability and antitrust issues. For investors considering investing in Johnson & Johnson, it is important to consider the current market conditions and the company’s long-term prospects. While the company has experienced a sharp decline in recent quarters, its strong brand name and diverse product portfolio may help it rebound in the future. Additionally, the company has a long history of dividend payments and share repurchases which could be attractive to long-term investors. Overall, Johnson & Johnson’s fourth quarter earnings results pose a difficult situation for investors. While the company has experienced recent difficulties, investors should take into account all available factors before making a decision about whether or not to invest in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
